Becaplermin

Generic Name: Becaplermin

Brand Names: Regranex

Drug Type: Biotech

CAS Number: 165101-51-9

Unique Ingredient Identifier: 1B56C968OA

Background: Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.

Indication: For topical treatment of skin ulcers (from diabetes)

Associated Conditions: Skin Ulcer

Clinical Trials

Evaluating an RhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing

Phase 2

Recruiting

Conditions: Anal Fistula
Complex Perianal Fistula

Interventions: Drug: RhPDGF-BB

First Posted Date: 2024-10-09

Last Posted Date: 2025-01-13

Lead Sponsor: Alexander Hawkins

Target Recruit Count: 12

Registration Number: NCT06632418

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

Phase 2

Recruiting

Conditions: Wound Healing
Surgical Wound
Graft Failure

Interventions: Drug: Saline
Drug: RhPDGF-BB

First Posted Date: 2024-10-09

Last Posted Date: 2025-05-15

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 40

Registration Number: NCT06634030

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Evaluation of ABSOLVE in Diabetic Foot Ulcers

Phase 2

Conditions: Diabetic Foot Ulcers

Interventions: Other: Placebo
Drug: RhPDGF-BB

First Posted Date: 2017-01-31

Last Posted Date: 2017-01-31

Lead Sponsor: Lynch Biologics LLC

Target Recruit Count: 40

Registration Number: NCT03037970

Locations: 🇬🇹
Centro Medico Militar, Guatemala City, Guatemala

A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer

Phase 3

Completed

Conditions: Diabetic Foot Ulcer

Interventions: Drug: BioChaperone PDGF-BB
Other: Standard of Care

First Posted Date: 2014-09-11

Last Posted Date: 2017-06-29

Lead Sponsor: Adocia

Target Recruit Count: 252

Registration Number: NCT02236793

Locations: 🇮🇳
Dr Jivraj Mehta Smarak Health Foundation, Ahmedabad, India
🇮🇳
IPGME & R and SSKM Hospital, Kolkata, India
🇮🇳
V.S. General Hospital & Sml NHL Municipal Medical College Sheth, Ahmedabad, India

and more 29 locations

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

Phase 2

Completed

Conditions: Lateral Epicondylitis

Interventions: Drug: rhPDGF-BB Injection
Drug: Placebo

First Posted Date: 2012-12-11

Last Posted Date: 2019-07-02

Lead Sponsor: BioMimetic Therapeutics

Target Recruit Count: 100

Registration Number: NCT01746420

Locations: 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸
Tucson Orthopaedic Institute, Tucson, Arizona, United States
🇺🇸
Coastal Orthopedics & Sports Medicine, Bradenton, Florida, United States

and more 3 locations

Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

Completed

Conditions: Foot Ulcer
Diabetic Foot
Diabetic Neuropathies
Diabetes Mellitus

Interventions: Drug: Becaplermin users
Other: Becaplermin nonusers

First Posted Date: 2010-11-05

Last Posted Date: 2016-07-19

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Registration Number: NCT01235260

Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer

Phase 1

Completed

Conditions: Diabetic Foot Ulcers

Interventions: Drug: Biochaperone PDGF-BB High dose
Drug: Biochaperone PDGF-BB Very Low Dose
Drug: Biochaperone PDGF-BB Low dose
Drug: Regranex

First Posted Date: 2010-04-02

Last Posted Date: 2014-12-15

Lead Sponsor: Virchow Group

Target Recruit Count: 192

Registration Number: NCT01098357

Locations: 🇮🇳
M.V. Hospital for Diabetes, Chennai, Tamilnadu, India
🇮🇳
Jain Institute of Vascular sciences, Bangalore, Karnataka, India
🇮🇳
Karnataka Institute of Diabetology, Bangalore, Karnataka, India

and more 4 locations

Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers

Phase 3

Completed

Conditions: MARTORELL'S ULCER
Hypertensive Leg Ulcer
Necrotic Angiodermatitis

Interventions: Drug: Duoderm Hydrogel™
Drug: becaplermin gel

First Posted Date: 2009-09-02

Last Posted Date: 2011-10-04

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 64

Registration Number: NCT00970697

Locations: 🇫🇷
Hospital Charles Foix, Ivry sur seine, Ile de France, France

The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: REGRANEX (becaplermin)
Other: REGRANEX (becaplermin) comparators

First Posted Date: 2007-08-20

Last Posted Date: 2016-07-19

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 4431

Registration Number: NCT00518102

Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers

Not Applicable

Conditions: Diabetic Foot Ulcers

Interventions: Drug: Regranex®
Drug: Hydrogel

First Posted Date: 2007-03-12

Last Posted Date: 2010-06-04

Lead Sponsor: Southern California Institute for Research and Education

Target Recruit Count: 60

Registration Number: NCT00446472

Locations: 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸
VA Long Beach Healthcare System, Long Beach, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy